187 related articles for article (PubMed ID: 17348843)
1. Targeting different signaling pathways with antisense oligonucleotides combination for cancer therapy.
Leonetti C; Zupi G
Curr Pharm Des; 2007; 13(5):463-70. PubMed ID: 17348843
[TBL] [Abstract][Full Text] [Related]
2. Antisense-based cancer therapeutics: are we there yet?
Rayburn ER; Wang H; Zhang R
Expert Opin Emerg Drugs; 2006 May; 11(2):337-52. PubMed ID: 16634705
[TBL] [Abstract][Full Text] [Related]
3. The future of antisense therapy: combination with anticancer treatments.
Biroccio A; Leonetti C; Zupi G
Oncogene; 2003 Sep; 22(42):6579-88. PubMed ID: 14528283
[TBL] [Abstract][Full Text] [Related]
4. Toxicology of antisense therapeutics.
Jason TL; Koropatnick J; Berg RW
Toxicol Appl Pharmacol; 2004 Nov; 201(1):66-83. PubMed ID: 15519609
[TBL] [Abstract][Full Text] [Related]
5. Overview of targeted therapies for cancer.
Finley RS
Am J Health Syst Pharm; 2003 Dec; 60(24 Suppl 9):S4-10. PubMed ID: 14717022
[TBL] [Abstract][Full Text] [Related]
6. Antisense treatment in human prostate cancer and melanoma.
Di Cresce C; Koropatnick J
Curr Cancer Drug Targets; 2010 Sep; 10(6):555-65. PubMed ID: 20482488
[TBL] [Abstract][Full Text] [Related]
7. Overcoming multidrug resistance using liposomal epirubicin and antisense oligonucleotides targeting pump and nonpump resistances in vitro and in vivo.
Lo YL; Liu Y; Tsai JC
Biomed Pharmacother; 2013 May; 67(4):261-7. PubMed ID: 23540284
[TBL] [Abstract][Full Text] [Related]
8. Combinatorial application of nucleic acid-based agents targeting protein kinases for cancer treatment.
Spänkuch B; Strebhardt K
Curr Pharm Des; 2008; 14(11):1098-112. PubMed ID: 18473857
[TBL] [Abstract][Full Text] [Related]
9. Setting sights on the treatment of ocular angiogenesis using antisense oligonucleotides.
Henry SP; Marcusson EG; Vincent TM; Dean NM
Trends Pharmacol Sci; 2004 Oct; 25(10):523-7. PubMed ID: 15380936
[TBL] [Abstract][Full Text] [Related]
10. Antitumor mechanisms of systemically administered epidermal growth factor receptor antisense oligonucleotides in combination with docetaxel in squamous cell carcinoma of the head and neck.
Thomas SM; Ogagan MJ; Freilino ML; Strychor S; Walsh DR; Gooding WE; Grandis JR; Zamboni WC
Mol Pharmacol; 2008 Mar; 73(3):627-38. PubMed ID: 18025070
[TBL] [Abstract][Full Text] [Related]
11. Antisense targeting protein kinase A type I as a drug for integrated strategies of cancer therapy.
Tortora G; Ciardiello F
Ann N Y Acad Sci; 2003 Dec; 1002():236-43. PubMed ID: 14751838
[TBL] [Abstract][Full Text] [Related]
12. Cancer therapy via modulation of micro RNA levels: a promising future.
Kota SK; Balasubramanian S
Drug Discov Today; 2010 Sep; 15(17-18):733-40. PubMed ID: 20692360
[TBL] [Abstract][Full Text] [Related]
13. RNA Therapeutics in Oncology: Advances, Challenges, and Future Directions.
MacLeod AR; Crooke ST
J Clin Pharmacol; 2017 Oct; 57 Suppl 10():S43-S59. PubMed ID: 28921648
[TBL] [Abstract][Full Text] [Related]
14. Disruption of metabolic pathways--perspectives for the treatment of cancer.
Araujo EP; Carvalheira JB; Velloso LA
Curr Cancer Drug Targets; 2006 Feb; 6(1):77-87. PubMed ID: 16475977
[TBL] [Abstract][Full Text] [Related]
15. Targeted delivery of antisense oligonucleotides to pancreatic β-cells.
Ämmälä C; Drury WJ; Knerr L; Ahlstedt I; Stillemark-Billton P; Wennberg-Huldt C; Andersson EM; Valeur E; Jansson-Löfmark R; Janzén D; Sundström L; Meuller J; Claesson J; Andersson P; Johansson C; Lee RG; Prakash TP; Seth PP; Monia BP; Andersson S
Sci Adv; 2018 Oct; 4(10):eaat3386. PubMed ID: 30345352
[TBL] [Abstract][Full Text] [Related]
16. Advances in targeting insulin-like growth factor signaling pathway in cancer treatment.
You L; Liu C; Tang H; Liao Y; Fu S
Curr Pharm Des; 2014; 20(17):2899-911. PubMed ID: 23944362
[TBL] [Abstract][Full Text] [Related]
17. A novel cancer therapy: combined liposomal hypoxia inducible factor 1 alpha antisense oligonucleotides and an anticancer drug.
Wang Y; Minko T
Biochem Pharmacol; 2004 Nov; 68(10):2031-42. PubMed ID: 15476674
[TBL] [Abstract][Full Text] [Related]
18. A novel integrated strategy (full length gene targeting) for mRNA accessible site tagging combined with microarray hybridization/RNase H cleavage to screen effective antisense oligonucleotides.
Sun Y; Duan M; Lin R; Wang D; Li C; Bo X; Wang S
Mol Vis; 2006 Nov; 12():1364-71. PubMed ID: 17149362
[TBL] [Abstract][Full Text] [Related]
19. Protein kinases as targets for cancer treatment.
Giamas G; Stebbing J; Vorgias CE; Knippschild U
Pharmacogenomics; 2007 Aug; 8(8):1005-16. PubMed ID: 17716234
[TBL] [Abstract][Full Text] [Related]
20. Advanced targeted therapies in cancer: Drug nanocarriers, the future of chemotherapy.
Pérez-Herrero E; Fernández-Medarde A
Eur J Pharm Biopharm; 2015 Jun; 93():52-79. PubMed ID: 25813885
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
